Finding effective biomarkers for pediatric traumatic brain injury

As traumatic brain injury (TBI) continues to affect children and young adults worldwide, research on reliable biomarkers grows as a possible aid in determining the severity of injury. However, many studies have revealed that diverse biomarkers such as S100B and myelin basic protein (MBP) have many l...

Full description

Bibliographic Details
Main Authors: Olena Y Glushakova, Alexander V Glushakov, Ronald L Hayes
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Brain Circulation
Subjects:
Online Access:http://www.braincirculation.org/article.asp?issn=2394-8108;year=2016;volume=2;issue=3;spage=129;epage=132;aulast=Glushakova
_version_ 1811202815517786112
author Olena Y Glushakova
Alexander V Glushakov
Ronald L Hayes
author_facet Olena Y Glushakova
Alexander V Glushakov
Ronald L Hayes
author_sort Olena Y Glushakova
collection DOAJ
description As traumatic brain injury (TBI) continues to affect children and young adults worldwide, research on reliable biomarkers grows as a possible aid in determining the severity of injury. However, many studies have revealed that diverse biomarkers such as S100B and myelin basic protein (MBP) have many limitations, such as their elevated normative concentrations in young children. Therefore, the results of these studies have yet to be translated to clinical applications. However, despite the setbacks of research into S100B and MBP, investigators continue to research viable biomarkers, notably glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1), as possible aids in medical decision making. Studies have revealed that GFAP and UCH-L1 actually are better predictors of injury progression than the before-mentioned biomarkers S100B and MBP. In addition, UCH-L1 has demonstrated an ability to detect injury while CT is negative, suggesting an ability to detect acute intracranial lesions. Here, we evaluate research testing levels of GFAP and UCH-L1 on children diagnosed with TBI and compare our results to those of other tested biomarkers. In a recent study done by Hayes et al., GFAP and UCH-L1 demonstrated the potential to recognize children with the possibility of poor outcome, allowing for more specialized treatments with clinical and laboratory applications. Although studies on GFAP and UCH-L1 have for the most part warranted positive results, further studies will be needed to confirm their role as reliable markers for pediatric TBI.
first_indexed 2024-04-12T02:45:59Z
format Article
id doaj.art-139089c814174ca391947b43d8ef1afe
institution Directory Open Access Journal
issn 2455-4626
language English
last_indexed 2024-04-12T02:45:59Z
publishDate 2016-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Brain Circulation
spelling doaj.art-139089c814174ca391947b43d8ef1afe2022-12-22T03:51:10ZengWolters Kluwer Medknow PublicationsBrain Circulation2455-46262016-01-012312913210.4103/2394-8108.192518Finding effective biomarkers for pediatric traumatic brain injuryOlena Y GlushakovaAlexander V GlushakovRonald L HayesAs traumatic brain injury (TBI) continues to affect children and young adults worldwide, research on reliable biomarkers grows as a possible aid in determining the severity of injury. However, many studies have revealed that diverse biomarkers such as S100B and myelin basic protein (MBP) have many limitations, such as their elevated normative concentrations in young children. Therefore, the results of these studies have yet to be translated to clinical applications. However, despite the setbacks of research into S100B and MBP, investigators continue to research viable biomarkers, notably glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1), as possible aids in medical decision making. Studies have revealed that GFAP and UCH-L1 actually are better predictors of injury progression than the before-mentioned biomarkers S100B and MBP. In addition, UCH-L1 has demonstrated an ability to detect injury while CT is negative, suggesting an ability to detect acute intracranial lesions. Here, we evaluate research testing levels of GFAP and UCH-L1 on children diagnosed with TBI and compare our results to those of other tested biomarkers. In a recent study done by Hayes et al., GFAP and UCH-L1 demonstrated the potential to recognize children with the possibility of poor outcome, allowing for more specialized treatments with clinical and laboratory applications. Although studies on GFAP and UCH-L1 have for the most part warranted positive results, further studies will be needed to confirm their role as reliable markers for pediatric TBI.http://www.braincirculation.org/article.asp?issn=2394-8108;year=2016;volume=2;issue=3;spage=129;epage=132;aulast=GlushakovaBiomarkersbrain injuryserumtraumatic brain injury
spellingShingle Olena Y Glushakova
Alexander V Glushakov
Ronald L Hayes
Finding effective biomarkers for pediatric traumatic brain injury
Brain Circulation
Biomarkers
brain injury
serum
traumatic brain injury
title Finding effective biomarkers for pediatric traumatic brain injury
title_full Finding effective biomarkers for pediatric traumatic brain injury
title_fullStr Finding effective biomarkers for pediatric traumatic brain injury
title_full_unstemmed Finding effective biomarkers for pediatric traumatic brain injury
title_short Finding effective biomarkers for pediatric traumatic brain injury
title_sort finding effective biomarkers for pediatric traumatic brain injury
topic Biomarkers
brain injury
serum
traumatic brain injury
url http://www.braincirculation.org/article.asp?issn=2394-8108;year=2016;volume=2;issue=3;spage=129;epage=132;aulast=Glushakova
work_keys_str_mv AT olenayglushakova findingeffectivebiomarkersforpediatrictraumaticbraininjury
AT alexandervglushakov findingeffectivebiomarkersforpediatrictraumaticbraininjury
AT ronaldlhayes findingeffectivebiomarkersforpediatrictraumaticbraininjury